AstraZeneca presented first Western patient data for its dual‑targeting CAR‑T therapy at ASH showing response rates comparable to earlier China-only studies. The preliminary dataset suggests similar efficacy and safety profiles across geographies for the autologous cell therapy, supporting the company’s global development strategy. AstraZeneca’s data could influence regulatory filings and investment in multicenter trials. Clarification: Dual‑target CAR‑T therapies are engineered to recognize two tumor antigens to reduce relapse through antigen escape.